uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (UCR)
2006 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, ISSN 1401-7431, Vol. 40, no 1, 17-24 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To analyse the cost-effectiveness of Taxus compared to a bare-metal stent in patients with coronary artery disease in the Swedish healthcare setting. DESIGN: A decision-analytic model combining clinical data on revascularization rates with Swedish unit costs for medical resources and utility data from the literature. RESULTS: For patients of moderate risk, the average cost per patient at 12 months is 72,200 SEK for Taxus and 66,900 SEK for a bare-metal stent, while the average cost for high risk patients is nearly equivalent (73,000 vs. 71,700 SEK). The cost per revascularization avoided is generally favourable, while the incremental cost per QALY gained varies depending on the assumptions made; from 2,351,000 SEK for patients of moderate risk at 12-months to cost saving at 24 months for high risk patients. Budget impact scenarios at 12 months are cost-neutral. CONCLUSION: The Taxus stent is cost-effective in high risk patients, particularly at 24 months. Although it may be less cost-effective for the general population, there is still a substantial offset of initial procedure costs through lower rate of repeat revascularizations.

Place, publisher, year, edition, pages
2006. Vol. 40, no 1, 17-24 p.
Keyword [en]
Clinical Trials, Coronary Arteriosclerosis/drug therapy/*economics/surgery, Coronary Artery Bypass/*economics, Cost-Benefit Analysis, Delivery of Health Care/*economics, Drug Delivery Systems/*economics, Health Care Costs, Humans, Models; Economic, Myocardial Revascularization/economics, Paclitaxel/administration & dosage/economics, Reoperation/economics, Stents/*classification/*economics/statistics & numerical data, Sweden, Taxus, Ticlopidine/administration & dosage/analogs & derivatives/economics
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-24894DOI: 10.1080/14017430500296323PubMedID: 16448993OAI: oai:DiVA.org:uu-24894DiVA: diva2:52668
Available from: 2007-02-27 Created: 2007-02-27 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16448993&dopt=Citation

Authority records BETA

James, Stefan

Search in DiVA

By author/editor
James, Stefan
By organisation
Department of Medical Sciences
In the same journal
Scandinavian Cardiovascular Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 372 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf